search

Further to a successful follow-up audit, IBBL (Integrated BioBank of Luxembourg) becomes the first biobank worldwide to be accredited for the next-generation 16S rRNA gene sequencing, a cutting-edge method that takes forward research into the human microbiome.

Approximately one year after issuing IBBL’s first accreditation, the Office Luxembourgeois d’Accréditation et de Surveillance (OLAS) confirmed its conformity with  ISO 17025, a norm that specifies the general requirements for the competence of testing and calibration laboratories. In addition to its positive feedback, the OLAS also expanded the scope to four additional testing methods:

  • DNA Cross-Linking Assessment
  • Long-Range PCR
  • Human sCD40L Quantification in Serum
  • 16S rRNA Gene Sequencing

Whereas the first three assays were developed in house for the purpose of biospecimen quality control, the latter, unique for biobanks, is a characterisation method dedicated to provide the scientific microbiome community with accurate and comprehensive data.

In this particular case, the next-generation 16S rRNA gene sequencing consists of identifying not only one single bacteria but the whole set of bacteria within a given sample of any kind, be it saliva or stool to name a few. Scientists have therefore a reliable full-length insight at their disposal, which enables them to move forward with their research.

“IBBL makes history in the biobanking world. The accreditation for the next-generation 16S rRNA gene sequencing assures confidence that IBBL successfully fulfils its mission as a biobank. Above all, we are proud to contribute to a promising research area in which Luxembourg is very active”, commented Marc Vandelaer, CEO of IBBL.

This announcement comes two weeks after the biobank successfully passed its follow-up audits for ISO 9001 (general quality management) and NF S96-900 (quality of biological resource centres). “Reaching those milestones would have never been possible without the continuous commitment of the staff and the management in the quality system. I am confident that we will keep on optimising our procedures to help minimise bias in research and maximise the potential of the biological samples donated by volunteers” ambitiously added Marc Vandelaer.

Read more

“An international view on the European healthtech market”

08-04-2024

Carole Brückler at the Luxembourg Ministry of the Economy speaks about why companies should attend the European Digital Healthtech Conference on 14-15 May 2024.
Read more

56 days until the 2024 European Digital HealthTech Conference

19-03-2024

Register for a unique conference exploring the challenges of bringing health technologies to the market and their solutions from 14 to 15 May 2024 in Luxembourg. A call for speakers is also open until 16 April.
Read more

New webinars for healthtech companies

13-09-2023

The Luxembourg HealthTech Cluster, managed by Luxinnovation, is paving the way for healthtech companies to navigate the complexities of launching their products on the European market through a series of webinars. The objective: to equip companies with insights that will facilitate their entry into the European market.
Read more

Applying for EIC Accelerator funding: How to succeed

30-05-2023

The EIC Accelerator is one of the most prestigious and attractive, but also one of the most competitive, funding instruments of Horizon Europe for individual start-ups and small companies developing and scaling up game-changing innovations. Three former Fit 4 Start participants who have received funding shared their best advice about do’s and don’ts at the Fit 4 Start Alumni event held on 25 May 2023.
Read more

Digital health solutions: enabling market launch for “European champions”

22-05-2023

There’s been progress on digital medical device regulations, but what existing barriers hinder the uptake of innovations on the European market. And what solutions are available? This was the focus of the European Digital Healthtech Hub Conference in Luxembourg, which emphasised the importance of harmonised standards and private investor engagement, best practices and other actions that can be taken.
Read more

Resources all news

Fermer